‘How do we create a sustainable hospital?’ This is the main question the Interdisciplinary Thesis Lab ‘Sustainable Hospitals’ centers around. On February 9th, eleven (including international) master students have started their master thesis research project related to this very question. Medical Delta’s Thesis Lab and the LDE Centre for Sustainability will supervise these students during their research.
Together, the students will research sustainability from different angles. Some examples of their research focus are: sustainable and safe treatments for patients, re-usage of medical instruments used in the operating theatre, and the implementation of green initiatives in the management and organization of care.
7% of the total Dutch CO2-footprint comes from the healthcare sector, including emission by power consumption, medicine and traveling. Moreover, hospitals produce a lot of waste, of which 20 to 30% comes from the operating theatre. This pollution increases when implementing new technologies and materials. Thus, there’s plenty of motivation to facilitate research on making the healthcare sector more sustainable. The research results from the master students will be made available in practical solutions to healthcare professionals, researchers, medical doctors and/or patients, ensuring the master students have an immediate influence on making hospital care more sustainable.
Read more about the Thesis Lab Sustainable Hospitals and the research projects taking place here: https://www.medicaldelta.nl/nieuws/interdisciplinair-thesis-lab-sustainable-hospitals-van-start (Dutch)
The African-European Tuberculosis Consortium (AE-TBC) is an international multisite group of African and European researchers who investigate the use of host biosignatures for the diagnosis of active TB disease. For over ten years, the LUMC groups of Infectious Diseases and Cell & Chemical Biology from Prof Annemieke Geluk and Dr Paul Corstjens respectively, have been partners of the EDCTP consortia for tuberculosis (among which AE-TBC). The AE-TBC recently won the prize for ‘Outstanding Research Team 2020, awarded by the EDCTP.
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
“This is an achievement in alignment with the mission of VODAN-Africa to generate continuous, real-time, high velocity clinical observational patient data from resource-limited communities that have not been well represented in digital health data. The key feature is that the data produced remains in the health facility only. It will not leave the health facility. Since the data is machine-actionable the input of the data only happens once; in the deployable architecture, the data is used for four parallel use cases” (VODAN to Africa, 2022).